Heterogeneity in Melanoma.

Area of Science:

• Oncology
• Cancer Biology

Background:

• Melanoma is a highly aggressive and therapy-resistant human cancer.
• Tumor heterogeneity presents a significant challenge in melanoma treatment.
• Despite therapeutic advancements, patient relapse remains a critical issue.

Purpose of the Study:

• To summarize current clinical melanoma classification and emerging layers of classification.
• To highlight the increasing importance of biomarkers for diagnosis and predicting therapy response.
• To discuss strategies for addressing tumor heterogeneity in melanoma treatment.

Main Methods:

• Review of clinical melanoma classifications.
• Analysis of emerging diagnostic and predictive biomarkers.
• Discussion of therapeutic strategies to overcome tumor heterogeneity.

Main Results:

• Current melanoma classification is evolving with new diagnostic layers.
• Biomarker analysis is becoming essential for patient selection in clinical trials.
• Tumor heterogeneity is identified as the primary driver of therapeutic failure and relapse.

Conclusions:

• Individualized therapy based on biomarkers is a promising approach.
• Future research aims to group melanomas using genetic and biologic biomarkers for outcome prediction.
• Developing complex therapies to target both bulk tumor and critical subpopulations is crucial for overcoming melanoma heterogeneity and preventing relapse.